VIPAS39

Across TCGA pan-cancer cohorts, VIPAS39 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated VIPAS39 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher VIPAS39 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VIPAS39 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, HNSC, and UCEC are the cancer types where VIPAS39 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
HNSC	OS	Median	II,III,IV	0.029	0.712	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.922	0.437	.025	10	view →
PRAD	DFS	Median	All	0.118	0.886	<.001	6	view →
LUSC	OS	Median	All	0.359	0.677	.033	6	view →
BLCA	OS	Median	III,IV	0.200	0.579	.037	3	view →
SARC	DFS	Median	All	0.127	0.611	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

VIPAS39–ESCA (OS)

Open the ESCA breakdown →